These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36724334)

  • 1. Aldosterone and Treatment-Resistant Hypertension.
    Leopold JA; Ingelfinger JR
    N Engl J Med; 2023 Feb; 388(5):464-467. PubMed ID: 36724334
    [No Abstract]   [Full Text] [Related]  

  • 2. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
    Whaley-Connell A; Johnson MS; Sowers JR
    Prog Cardiovasc Dis; 2010; 52(5):401-9. PubMed ID: 20226958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone receptor antagonists: current perspectives and therapies.
    Guichard JL; Clark D; Calhoun DA; Ahmed MI
    Vasc Health Risk Manag; 2013; 9():321-31. PubMed ID: 23836977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone and the risk of hypertension.
    Xanthakis V; Vasan RS
    Curr Hypertens Rep; 2013 Apr; 15(2):102-7. PubMed ID: 23378101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.
    Valaiyapathi B; Calhoun DA
    Curr Hypertens Rep; 2018 Mar; 20(3):23. PubMed ID: 29556729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Primary hyperaldosteronism: should we pose its systematic detection at health centres?].
    Maciá-Bobes C; Ronzón-Fernández A; Castaño-Fernández G; Botas-Cervero P
    Aten Primaria; 2006 Feb; 37(2):104-7. PubMed ID: 16527118
    [No Abstract]   [Full Text] [Related]  

  • 8. Resistant Hypertension: A Clinical Perspective.
    Hannah-Shmouni F; Gubbi S; Spence JD; Stratakis CA; Koch CA
    Endocrinol Metab Clin North Am; 2019 Dec; 48(4):811-828. PubMed ID: 31655778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension.
    Martínez-Martínez E; Calvier L; Fernández-Celis A; Rousseau E; Jurado-López R; Rossoni LV; Jaisser F; Zannad F; Rossignol P; Cachofeiro V; López-Andrés N
    Hypertension; 2015 Oct; 66(4):767-75. PubMed ID: 26238446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of aldosterone antagonists in the management of resistant hypertension.
    Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conn syndrome as cause of stubborn hypertension. Which hypertensives should you screen?].
    Reincke M
    MMW Fortschr Med; 2003 Feb; 145(9):37-40. PubMed ID: 12666528
    [No Abstract]   [Full Text] [Related]  

  • 12. Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma.
    Amar L; Lorthioir A; Azizi M; Plouin PF
    Eur J Endocrinol; 2015 Mar; 172(3):R125-9. PubMed ID: 25315875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent Progress in Primary Aldosteronism].
    Shibata H
    Nihon Naika Gakkai Zasshi; 2017 Feb; 106(2):319-26. PubMed ID: 30182662
    [No Abstract]   [Full Text] [Related]  

  • 14. Vascular Consequences of Aldosterone Excess and Mineralocorticoid Receptor Antagonism.
    Chrissobolis S
    Curr Hypertens Rev; 2017; 13(1):46-56. PubMed ID: 28245785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy-resistant hypertension--the value of aldosterone antagonists].
    Quack I; Reincke M; Rump LC
    MMW Fortschr Med; 2007 Nov; 149(46):39-40. PubMed ID: 18069192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Hyperaldosteronism: Approach to Diagnosis and Management.
    El-Asmar N; Rajpal A; Arafah BM
    Med Clin North Am; 2021 Nov; 105(6):1065-1080. PubMed ID: 34688415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aldosterone in resistant hypertension: implications for pathogenesis and therapy.
    Epstein M; Calhoun DA
    Curr Hypertens Rep; 2007 Apr; 9(2):98-105. PubMed ID: 17442219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
    Funder JW
    Am J Cardiovasc Drugs; 2007; 7(3):151-7. PubMed ID: 17610342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.